Form 8-K - Current report:
SEC Accession No. 0001628280-23-007646
Filing Date
2023-03-13
Accepted
2023-03-13 09:25:24
Documents
12
Period of Report
2023-03-13
Items
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 8-K vnda-20230313.htm   iXBRL 8-K 35331
  Complete submission text file 0001628280-23-007646.txt   174585

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT vnda-20230313.xsd EX-101.SCH 1957
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT vnda-20230313_lab.xml EX-101.LAB 24945
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT vnda-20230313_pre.xml EX-101.PRE 13178
6 EXTRACTED XBRL INSTANCE DOCUMENT vnda-20230313_htm.xml XML 11272
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

EIN.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34186 | Film No.: 23725964
SIC: 2834 Pharmaceutical Preparations